Bioventus Inc. (BVS) News

Bioventus Inc. (BVS): $2.09

-0.02 (-0.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter BVS News Items

BVS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BVS News Highlights

  • BVS's 30 day story count now stands at 3.
  • Over the past 18 days, the trend for BVS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest BVS News From Around the Web

Below are the latest news stories about BIOVENTUS INC that investors may wish to consider to help them evaluate BVS as an investment opportunity.

15 Largest Orthopedic Companies in the World

In this article, we will take a look at the 15 largest orthopedic companies in the world. If you want to see more companies in this selection, go to the 5 Largest Orthopedic Companies in the World. The orthopedic industry has staged a comeback in the last two years following a dismal 2020 due to […]

Yahoo | January 14, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday!

William White on InvestorPlace | January 12, 2023

Bioventus to Present at the 41st Annual J.P. Morgan Healthcare Conference

DURHAM, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 5:15 p.m. PT (8:15 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available until February 10, 2023. About BioventusBio

Yahoo | January 4, 2023

2022 Year in Review: Layoffs hit Triangle biotech, pharma companies

After record levels of funding poured into life sciences companies during the pandemic, economic conditions turned 2022 into a much more difficult year.

Yahoo | December 27, 2022

Durham's Bioventus slashing headcount to rein in expenses

Weeks after releasing the results from a poor quarter, a Durham health care company is undergoing a restructuring that will eliminate a significant number of jobs as the firm looks to rein in costs. Bioventus (Nasdaq: BVS) disclosed this week a restructuring that is aimed at aligning the company's "organizational and management cost structure to improve profitability and cash flow." The restructuring will mostly occur through a broad headcount reduction across all company functions, including its corporate office in Durham and a manufacturing facility in Memphis, Tennessee, said Dave Crawford, Bioventus vice president of investor relations.

Yahoo | December 9, 2022

Why this Durham firm's stock is down more than 70% this month

A Durham health care company is evaluating its future financial obligations after a shaky earnings report.

Yahoo | November 29, 2022

Bioventus Issues Revised Third Quarter Results; Updates Full-Year 2022 Financial Guidance

DURHAM, N.C., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today amended its previously announced financial results for the three and nine months ended October 1, 2022. Due to the adverse effect on the previously announced third quarter 2022 financial results and revenue guidance that resulted from additional rebate claims related to certain of the Company’s products and a non-cash impairment cha

Yahoo | November 21, 2022

Bioventus Files for Extension to File Form 10-Q for the Period Ended October 1, 2022

DURHAM, N.C., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the Company has filed a Form 12b-25, Notification of Late Filing for its Quarterly Report on Form 10-Q for the period ended October 1, 2022. As a result of the recent decline in the Company’s market capitalization subsequent to its previously announced financial results for the third quarter of 2022 ("Q3 Earnings Release")

Yahoo | November 16, 2022

Bioventus Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

Bioventus ( NASDAQ:BVS ) Third Quarter 2022 Results Key Financial Results Revenue: US$137.1m (up 26% from 3Q 2021). Net...

Yahoo | November 10, 2022

Why Shares of Bioventus Fell 14% on Wednesday

Shares of Bioventus (NASDAQ: BVS) fell 14% on Wednesday. The medical device company's stock closed on Tuesday at $3 a share, then opened on Wednesday at $2.90. Bioventus focuses on making treatments that enhance the body's natural healing process, such as ultrasound bone healing systems and bone graft materials.

Yahoo | November 9, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5301 seconds.